Results 101 to 110 of about 74,509 (297)
From Pharmacist to Pharma: Advice on Career Pathways in Drug Development
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, EarlyView.ABSTRACT There are ever‐expanding opportunities in drug development for pharmacists. Mechanisms available to train post‐Doctor of Pharmacy (PharmD) graduates for careers in drug development have undergone dramatic evolution, particularly in the past decade.
William P. Petros, J. Robert Powell
wiley +1 more source
Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes. [PDF]
Ann Hum GenetABSTRACT Pharmacogenomics, the use of germline genomic data to guide prescription to improve effective and safer medication, holds promise as a clinical intervention. To date in most health systems, there has been limited uptake of pharmacogenomic testing confined to a few single drug–gene associations.
McDermott JH +3 more
europepmc +2 more sources
PLoS Computational Biology, 2012 There is great variation in drug-response phenotypes, and a "one size fits all" paradigm for drug delivery is flawed. Pharmacogenomics is the study of how human genetic information impacts drug response, and it aims to improve efficacy and reduced side ...
Konrad J Karczewski +3 more
doaj +1 more source
The Journal of Clinical Pharmacology, EarlyView.Abstract Targeted therapies and immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in metastatic renal cell carcinoma (mRCC) but are often associated with high rates of adverse events, leading to dose reductions or treatment discontinuation.
Zhiyuan Tan +4 more
wiley +1 more source
DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. [PDF]
, 2017 INTRODUCTION:The perioperative pain experience shows great interindividual variability and is difficult to predict. The mu-1 opioid receptor gene (OPRM1) is known to play an important role in opioid-pain pathways.
Chidambaran, Vidya +8 more
core +1 more source
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
The Journal of Clinical Pharmacology, EarlyView.Abstract Recognition of benefits and adverse effects of therapies in earlier clinical trial phases could improve the safety, efficiency, and cost of clinical trials. Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP‐1 RA, SUGAR‐DM‐HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and ...
Jessica Chadwick +17 more
wiley +1 more source
The Future of Drug Development: The Economics of Pharmacogenomics [PDF]
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D).
John A. Vernon, W. Keener Hughen
core
The Journal of Clinical Pharmacology, EarlyView.Abstract Corticosteroids are effective anti‐cancer agents for treating hematologic malignancies in children. However, avascular necrosis (AVN) is a common and debilitating adverse effect, leading to bone death and impacting long‐term quality of life. This study aimed to uncover the genetic factors contributing to corticosteroid‐induced AVN in a well ...
Miguel Cordova‐Delgado +9 more
wiley +1 more source